News & Events

News


Tuesday September 17, 2019

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

- Phase III Data Analyses Evaluate the Long-Term Benefit of INGREZZA® (valbenazine) 40 mg and Early Response to Treatment in Patients with Tardive Dyskinesia - Data Examine Effect of Opicapone on COMT Enzyme and Levodopa Concentration in Patients with Parkinson's Disease - Phase 1b Data Analyze


Wednesday September 11, 2019

Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors

SAN DIEGO , Sept. 11, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Leslie V. Norwalk to its Board of Directors. Ms. Norwalk formerly served as Acting Administrator for the Centers for Medicare & Medicaid Services (CMS) under the George W.


Wednesday August 28, 2019

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Aug. 28, 2019 /PRNewswire/ --  Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy , Chief Financial Officer, will present at the Baird 2019 Global Healthcare Conference at


Monday August 05, 2019

AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women

- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients - Clinical trials in women with heavy menstrual bleeding (HMB) associated with uterine fibroids showed a statistically significant reduction in HMB with elagolix, in combination with add-back


Monday July 29, 2019

Neurocrine Biosciences Reports Second Quarter 2019 Financial Results

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $180.5 Million with Approximately 31,600 TRx FDA Accepts Opicapone New Drug Application with PDUFA Date of April 26, 2020 Congenital Adrenal Hyperplasia Program Advances with Initiation of Adaptive Pediatric Trial and FDA Input on Adult

Events